FibroBiologics Files 2024 Second Quarter Report

8/7/24 6:52:58 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FBLG alert in real time by email

HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission.

The filing can be viewed through a link on FibroBiologics' website at https://ir.fibrobiologics.com/sec-filings/quarterly-reports.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:

[email protected]

Investor Relations:

Nic Johnson

Russo Partners

212-845-4242

[email protected]

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697

[email protected]

Get the next $FBLG alert in real time by email

Date	Price Target	Rating	Analyst
10/30/2024	$12.00	Buy	H.C. Wainwright
9/24/2024	$12.00	Buy	Maxim Group

FibroBiologics Files 2024 Second Quarter Report

Chat with this insight

Recent Analyst Ratings for
$FBLG

$FBLG
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on FibroBiologics with a new price target

Maxim Group initiated coverage on FibroBiologics with a new price target

$FBLG
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

$FBLG
Press Releases

Fastest customizable press release news feed in the world

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

$FBLG
SEC Filings

FibroBiologics Inc. filed SEC Form 8-K: Leadership Update, Other Events

FibroBiologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

FibroBiologics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

$FBLG
Market Insights

Live Market Insights

$FBLG
Leadership Updates

Live Leadership Updates

FibroBiologics Highlights Preliminary Proof-Of-Concept For Novel Artificial Thymus Organoid Technology

FibroBiologics Files Prospectus Relates To Resale Of Up To 16M Shares Of Common Stock By GEM

FibroBiologics To Join Russell 2000 Index; Effective July 1 Following Annual Reconstitution

FibroBiologics Set to Join Russell 2000® Index

FibroBiologics Appoints Ruben A. Garcia as General Counsel

$FBLG
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Niklas Victoria Ninon Olivia

SEC Form 4 filed by Director Link Matthew

SEC Form 4 filed by Director Hoffman Robert E.

FibroBiologics Files 2024 Second Quarter Report

Chat with this insight

Recent Analyst Ratings for $FBLG

$FBLG Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on FibroBiologics with a new price target

Maxim Group initiated coverage on FibroBiologics with a new price target

$FBLG Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

$FBLG Press Releases

Fastest customizable press release news feed in the world

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

$FBLG SEC Filings

FibroBiologics Inc. filed SEC Form 8-K: Leadership Update, Other Events

FibroBiologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

FibroBiologics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

$FBLG Market Insights

Live Market Insights

$FBLG Leadership Updates

Live Leadership Updates

FibroBiologics Highlights Preliminary Proof-Of-Concept For Novel Artificial Thymus Organoid Technology

FibroBiologics Files Prospectus Relates To Resale Of Up To 16M Shares Of Common Stock By GEM

FibroBiologics To Join Russell 2000 Index; Effective July 1 Following Annual Reconstitution

FibroBiologics Set to Join Russell 2000® Index

FibroBiologics Appoints Ruben A. Garcia as General Counsel

$FBLG Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Niklas Victoria Ninon Olivia

SEC Form 4 filed by Director Link Matthew

SEC Form 4 filed by Director Hoffman Robert E.

Recent Analyst Ratings for
$FBLG

$FBLG
Analyst Ratings

$FBLG
Insider Purchases

$FBLG
Press Releases

$FBLG
SEC Filings

$FBLG
Market Insights

$FBLG
Leadership Updates

$FBLG
Insider Trading